ProShare Advisors
ABCL icon

ProShare Advisors’s AbCellera Biologics ABCL Stock Holding History

ProShare Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.6K Sell
10,011
-3,551
-26% -$17.4K ﹤0.01% 1806
2026
Q1 		$47.3K Buy
13,562
+322
+2% +$1.16K ﹤0.01% 1794
2025
Q4 		$45.3K Buy
13,240
+2,594
+24% +$11.6K ﹤0.01% 1966
2025
Q3 		$53.5K Sell
10,646
-500
-4% -$2.2K ﹤0.01% 1927
2025
Q2 		$38.2K Sell
11,146
-2,297
-17% -$5.72K ﹤0.01% 2024
2025
Q1 		$30K Sell
13,443
-547
-4% -$1.57K ﹤0.01% 2002
2024
Q4 		$41K Sell
13,990
-3,422
-20% -$9.53K ﹤0.01% 2204
2024
Q3 		$45.3K Sell
17,412
-740
-4% -$2.05K ﹤0.01% 1987
2024
Q2 		$53.7K Sell
18,152
-2,366
-12% -$8.95K ﹤0.01% 1742
2024
Q1 		$92.9K Buy
20,518
+1,978
+11% +$10.1K ﹤0.01% 1834
2023
Q4 		$106K Sell
18,540
-376
-2% -$1.74K ﹤0.01% 1774
2023
Q3 		$87K Buy
18,916
+234
+1% +$1.42K ﹤0.01% 1656
2023
Q2 		$121K Sell
18,682
-25,638
-58% -$175K ﹤0.01% 1666
2023
Q1 		$334K Sell
44,320
-5,989
-12% -$54.4K ﹤0.01% 1146
2022
Q4 		$510K Buy
50,309
+3,495
+7% +$40.4K ﹤0.01% 953
2022
Q3 		$463K Buy
46,814
+1,391
+3% +$15.3K ﹤0.01% 927
2022
Q2 		$484K Buy
45,423
+15,940
+54% +$135K ﹤0.01% 948
2022
Q1 		$287K Sell
29,483
-10,170
-26% -$96.3K ﹤0.01% 1654
2021
Q4 		$567K Buy
+39,653
New +$602K ﹤0.01% 1358

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

ProShare Advisors's ABCL Position: Q2 2026 in Review

ProShare Advisors reduced its AbCellera Biologics (ABCL) stake by 26% in Q2 2026, selling an estimated $17.4K and leaving 10,011 shares worth $78.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

ProShare Advisors first reported a position in ABCL in Q4 2021 and has held it in 19 quarters since. The position peaked at $567K in Q4 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • ProShare Advisors held 10,011 shares of AbCellera Biologics worth $78.6K as of Q2 2026.
  • ProShare Advisors sold 3,551 AbCellera Biologics shares in Q2 2026, an estimated $17.4K.
  • AbCellera Biologics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1806 holding.
  • ProShare Advisors first reported a position in AbCellera Biologics in Q4 2021 and has held it in 19 quarters since.
  • ProShare Advisors's AbCellera Biologics position peaked at $567K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.